The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
Recommendations
As issued by the authors
IL-18 is a uniquely specific biomarker for many sJIA subsets most in need of new therapies and may define a class of diseases mediated by IL-18 excess (broad agreement)
Leveraging IL-18 remains the most promising lead for refractory sJIA, as it may mechanistically explain the pathophysiology and lead to more targeted therapies (consensus)
Original publication
The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis? Pediatr Rheumatol Online J. Published 5 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →